|
EP3797172A1
|
|
Biomarker methods for treatment of atopic disease by immunotherapy
|
|
TW202037379A
|
|
Pharmaceutical-grade house dust mite allergen extracts
|
|
EP3463449A1
|
|
Immunogenic proteins and fragments thereof from allergenic mites
|
|
US2018185582A1
|
|
An injector comprising a safety pin
|
|
AU2014369866A1
|
|
Peptide combinations and uses thereof in treating dust mite allergy
|
|
AU2014277697A1
|
|
Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
|
|
CA2915743A1
|
|
Molecular identification of allergy causing mites by pcr
|
|
CA2870399A1
|
|
Plant profilin polypeptides for use in non-specific allergy immunotherapy
|
|
WO2012049312A1
|
|
Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
|
|
CN103547287A
|
|
Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
|
|
CN103327988A
|
|
Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
|
|
BR112012030705A2
|
|
pharmaceutical product comprising mite allergen extract (s) and a method for the manufacture thereof
|
|
WO2010146171A1
|
|
Novel manner of administering allergen in allergen specific immunotherapy
|
|
DK200901259A
|
|
Pharmaceutical product for Allergy Vaccination
|
|
AU2009305406A1
|
|
Pharmaceutical product for up-dosing of allergy vaccine
|
|
CN102014954A
|
|
Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
|
|
AU2009203733A1
|
|
Allergy vaccine composition for mucosal administration
|
|
AU2008309654A1
|
|
Process for producing mature recombinant Mite Group I allergen
|
|
CN101678012A
|
|
The allergen dosage form that comprises antihistaminic
|
|
WO2008119762A1
|
|
A method for mite production
|
